The abstract is read at the publisher; the summary is JClub's.
An IRAOOPcap of $2,000 annual out-of-pocket costs for Medicare Part D beneficiaries with newly diagnosed multiple myeloma is projected to yield 0.17–0.18 life-years gained in ages 66–75 under realistic-to-best IMiD adherence scenarios.
- Why it matters: High out-of-pocket costs for oral IMiDs may reduce adherence, but post-implementation survival effects of the IRAOOPcap were not yet observed, leaving a key evidence gap for policy impact.
- What they did: Using survival submodels from two CISNET natural history models parameterized with SEER-Medicare data (2012–2021), the study simulated Medicare Part D beneficiaries with NDMM aged 66–75 and ≥76 under scenarios shifting IMiD use from 0% to 100%.
- The result: Across models, realistic/best-case scenarios produced 0.17–0.18/1.10–1.35 life-years gained for ages 66–75 and 0.20–0.26/1.29–1.53 for ages ≥76, translating to 4,164–5,005/26,893–32,347 population-level life-years gained in 2025.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.